The Graves Disease Overactive Thyroid Market comprises medications for managing the symptoms of Graves disease and is used to stabilize thyroid hormone levels in the body. Graves disease, also known as toxic diffuse goiter, is an autoimmune disease that results in the overproduction of thyroid hormones. Treatment options include antithyroid medications, radioactive iodine therapy, surgery, and immunotherapy. The medications are effective in reducing thyroid hormone production and controlling the symptoms.

The Global Graves Disease Overactive Thyroid Market is estimated to be valued at US$ 570.2 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Graves Disease Overactive Thyroid Market are AbbVie Inc., Pfizer Inc., RLC LABS, Inc., Merck KGaA, Eisai Co., Ltd., Novartis AG, Mylan N.V., Aspen Pharmacare Holdings Ltd, Sanofi, GlaxoSmithKline plc, AstraZeneca, Horizon Therapeutics plc, Alara Pharmaceutical Corporation, Antares Pharma, Inc., Apitope Technology (Bristol) Ltd., IONIS Pharmaceuticals, Inc., Immunovant, Inc., HanAll Biopharma Co., Ltd., Cara Therapeutics. Key players are focusing on developing new innovative therapeutics for better management of Graves Disease Overactive Thyroid Market Size with minimal side effects.

The growing prevalence of Graves disease worldwide owing to changing lifestyle and increasing environmental risk factors, is driving the demand for Graves disease treatment medications. As per estimates around 1 in every 200 individuals suffers from Graves disease globally.

Increasing investment by key players in emerging regions such as Asia Pacific and Latin America for facility expansion and new product launches is helping drive the Graves Disease Overactive Thyroid Market. This will help cater to the unmet needs of underserved patient populations in these regions.

Gets More Insights on, Graves Disease Overactive Thyroid Market

Explore Related Article on, Chagas Disease Treatment Market